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Abstract. We investigate influence of human recombinant erythropoietin different dosage on blood 
flow velocity and morphological changes in liver during ischemic and reperfusion injury. It was 
proved what optimal preconditioning dosage is 50 IU/kg.  
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Ischemic and reperfusion complications take 
leading role in development internal organs different 
diseases as liver injury during surgical interventions 
with decreasing blood supply.  
The possibility of direct and remote ischemic 
preconditioning simulation is an experimental 
pharmacology keystone.  
The greatest interest among a number of 
substances for pharm modeling ischemic 
preconditioning, it is a recombinant human 
erythropoietin showed to be effective in protecting to 
myocardial and brain tissues ischemia/reperfusion 
injuries protection [4, 5]. 
However data of human recombinant 
erythropoietin usage in liver ischemia/reperfusion 
correction are rather contradictory .  
The goal of our investigation was to assess the 
influence of human recombinant erythropoietin 
different dosage on blood flow velocity as 
microcirculation changes evaluation screening method.   
Materials and methods: 70 white (male and 
female) 280-300g rates were used. Animals were 
grouped in 7 sets by 10 rates each. I/R group: 
reperfusion 30 minutes followed by 30 minutes of 
ischemia. I/R+EPO in dose 5 IU/kg group: 
reperfusion 30 minutes followed by 30 minutes of 
ischemia pretreated with 5 IU/kg human recombinant 
erythropoietin. I/R+EPO in dose 25 IU/kg group: 
reperfusion 30 minutes followed by 30 minutes of 
ischemia pretreated with 25 IU/kg human recombinant 
erythropoietin. I/R+EPO in dose 50 IU/kg group: 
reperfusion 30 minutes followed by 30 minutes of 
ischemia pretreated with 50 IU/kg human recombinant 
erythropoietin. I/R+EPO in dose 100 IU/kg group: 
reperfusion 30 minutes followed by 30 minutes of 
ischemia pretreated with 100 IU/kg human 
recombinant erythropoietin. I/R+EPO in dose 200 
IU/kg group:  reperfusion 30 minutes followed by 30 
minutes of ischemia pretreated with 200 IU/kg human 
recombinant erythropoietin. I/R+EPO in dose 500 
IU/kg group:  reperfusion 30 minutes followed by 30 
minutes of ischemia pretreated with 500 IU/kg human 
recombinant erythropoietin. All interventions were 
made under general anesthesia («Zolitel 100» 60 
mg/kg with chloral hydrate 125 mg/kg 
intraperitonealy). 
Transient deep liver ischemia reproduced by 
temporary hepatoduodenal ligament compression for 
30 min [1, 2, 3].  
Human recombinant erythropoietin («Epocrin» 
obtained from StateSRU  ultrapure biological drags 
FMBA FGUP, Russia) injected intraperitonealy 50 
IU/kg 30 min before ischemia.  
Blood flow velocity was measured by Biopaq 
systems MP150 with TSD144 probe in perfusion units 
(PU).   
Direct ischemic preconditioning was reproduced 
30 min ahead of deep ischemia episode by 10 min 
hepatoduodenal  ligament compression.  
For control method we used standard histological 
investigation with hematoxylin/eosin dye. 
During research we found blood flow velocity 
were on 850.48± 19.75 PU level. Deep ischemia 
episode leads to perfusion dropping to zero level with 
restoration on 1 minute till 120.17±4.7 PU,  changed 
with transient hyperemia 1983.22±63.35 PU on 15 
minute and decreasing till 611.63±27.43 PU on 
reperfusion 30 minute. According obtained data the 
best time for assessing is reperfusion 15 minute as 
maximum volatile point. 
Direct ischemic preconditioning largely 
decrease transient hyperemia till 1338.46± 14.06 
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PU on 15 minute, changed by 500.16± 16.41 PU on 
30 minute blood flow velocity investigation. 
Human recombinant erythropoietin injection 
in doses 5, 25, 50, 100, 200, 500 IU leads to 
transient hyperemia decreasing with maximum 
effect in 200 and 500 IU/kg doses (Table 1). 
Statistic analysis revealed no differences between 
groups with 200 and 500 IU/kg, moreover small 
distinctions between groups with 50 and 100 IU/kg 
were found and dose of 50 IU/kg we decided to use 
later as safer one.    
Table 1 
Human recombinant erythropoietin different dosage effect on blood flow velocity in liver microvascular vessels during 
ischemia and reperfusion (PU) (М±m, n=10) 
Groups 15 reperfuson minute 
I/R 1983.22±63.35* 
I/R+EPO in dose 5 IU/kg 1856.38±72.12** 
I/R+EPO in dose 25 IU/kg 1789.28±22.58** 
I/R+EPO in dose 50 IU/kg 1447.93±23.72** 
I/R+EPO in dose 100 IU/kg 1367.81±34.28** 
I/R+EPO in dose 200 IU/kg 1295.26±54.82** 
I/R+EPO in dose 500 IU/kg 1308.14±31.87** 
I/R+IPC 1338.46±14.06** 
Note
*
 – p≤0.05 versus against intact group data, ** – р≥0.05 – versus against ischemia/reperfusion group data. 
Histological examination showed complex of 
nonspecific changes caused by ischemic damage and 
characterized by portal vessels and sinusoids desolation 
combined with pronounced dystrophic, necrobiotic 
hepatocytes changes and microcirculation impairment 
(Fig. 1.). Reperfusion injury appear as severe sinusoidal 
dilation with diapedetic bleeding increasing dystrophic 
and necrobiotic changes (Fig. 2.).  
Human recombinant erythropoietin  injection 
(Epocrin)  50 IU/kg decreased  hepatocelular damage 
and manifested in necrobiotic changes absence in late 
stages of 30 minute of ischemia and their small 
presence at 30 minute of reperfusion. It’s characteristic 
in group with EPO to haven’t microthrombosis  and 
stromal leakage (Fig. 3, Fig. 4.).   
Figure 1. Ischemic liver injury: centrolobular anaemia, compact grain liver dystrophy. Hematoxylin and  eosin dye. 
Microphoto. А) Х 200. Б) Х400 
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Figure 2. Reperfusion liver injury: severe necrobiotic and dystrophic changes, diapedetic haemorrhage focus. 
Hematoxylin and  eosin dye. Microphoto. А) Х 200. Б) Х400 
Figure 3. 50 IU/kg erythropoietin influence on ischemic liver injury: mild centrolobular enimia and absence 
of dystrophic changes. Hematoxylin and  eosin dye. Microphoto. А) Х 200. Б) Х400 
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Figure 4. IU/kg erythropoietin influence on reperfusion liver injury: venous hyperaemia, absence of hemorrhage. 
Hematoxylin and  eosin dye. Microphoto. А) Х 200. Б) Х400. 
Conclusion. Thereby the study found that the 
recombinant erythropoietin dose-dependently 
prevented the development of reactive hyperemia 15 
minute reperfusion. Prekonditsionuyuschey optimal 
dose is 50 IU/kg. The positive effect of recombinant 
erythropoietin also confirmed by morphological 
study and is manifested in the absence of thrombosis 
and hemorrhage, minimum changes in the severity of 
necrobiotic a tsentrolobulyarnyh necrosis and venous 
plethora 
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